[1] SOUSA Á F L, QUEIROZ A A F L N, OLIVEIRA L B, et al. Deaths among the elderly with ICU infections[J]. Rev Bras Enferm, 2017, 70(4):733-739. [2] ESME M, TOPELI A, YAVUZ B B, et al. Infections in the elderly critically-ill patients[J]. Front Med: Lausanne, 2019, 6:118. [3] 刘亚军.抗菌药物引起老年患者不良反应的临床分析[J]. 临床医学研究与实践,2017, 2(16):34-35. [4] HASHEMIAN S M R, FARHADI T, GANJPARVAR M. Linezolid: a review of its properties, function, and use in critical care[J]. Drug Des Devel Ther, 2018, 12:1759-1767. [5] LEADER R, HACKETT J, ALLAN A, et al. Linezolid-induced pancytopenia[J]. BMJ Case Rep, 2018, 2018:bcr2018225480. [6] CAZAVET J, BOUNES F V, RUIZ S, et al. Risk factor analysis for linezolid-associated thrombocytopenia in critically ill patients[J]. Eur J Clin Microbiol Infect Dis, 2020, 39(3):527-538. [7] HANAI Y, MATSUO K, OGAWA M, et al. A retrospective study of the risk factors for linezolid-induced thrombocytopenia and anemia[J]. J Infect Chemother, 2016, 22(8):536-542. [8] 沈赟,秦艳,陈喆,等. Logistic 模型联合ROC曲线对利奈唑胺致老年患者血小板减少的预测分析[J]. 中国医院药物杂志, 2020, 40(24):2544-2548. [9] 王立刚, 刘智勇, 杜晓明. 利奈唑胺致血小板减少症的相关影响因素分析[J].中国药物评价, 2018, 35(6):450-454. [10] DAI Y, JIANG S, CHEN X, et al. Analysis of the risk factors of linezolid-related haematological toxicity in Chinese patients[J]. J Clin Pharm Ther, 2021, 46(3):807-813. [11] WASSERMAN S, DENTI P, BRUST J C M, et al. Linezolid pharmacokinetics in south african patients with drug-resistant tuberculosis and a high prevalence of HIV coinfection[J]. Antimicrob Agents Chemother, 2019, 63(3):e02164-e02118. |